One of the lessons learned during the H1N1 pandemic is the U.S. needs a faster way to develop flu vaccines.
But steps are being taken to make that happen.
Novartis is opening this cell-based flu vaccine plant in North Carolina.
It will be able to make 150-million doses in six months, without the use of eggs.
The plant is still a few years away from producing vaccine, and cell-based vaccines are not yet approved in the U.S.